Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 1351 to 1400 of 2013

TitleReference numberPublishedLast updated
Angioplasty and stenting to treat peripheral arterial disease causing refractory erectile dysfunctionHTG402
Mechanical clot retrieval for treating acute ischaemic strokeHTG403
Normothermic extracorporeal preservation of hearts for transplantation following donation after brainstem deathHTG404
Nivolumab for treating advanced (unresectable or metastatic) melanomaTA384
Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits)HTG401
Fractures (non-complex): assessment and managementNG38
Major trauma: assessment and initial managementNG39
Major trauma: service deliveryNG40
Spinal injury: assessment and initial managementNG41
Sunlight exposure: risks and benefitsNG34
Skin cancer preventionPH32
TNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritisTA383
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicatedTA377
Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapyTA378
Nintedanib for treating idiopathic pulmonary fibrosisTA379
Panobinostat for treating multiple myeloma after at least 2 previous treatmentsTA380
Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal)TA382
Percutaneous coblation of the intervertebral disc for low back pain and sciaticaHTG397
Percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciaticaHTG398
Percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back painHTG399
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failedTA375
Guidance on the use of imatinib for chronic myeloid leukaemiaTA70
Older people: independence and mental wellbeingNG32
Care of dying adults in the last days of lifeNG31
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritisTA373
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapyTA374
Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tearsTA369
Bortezomib for previously untreated mantle cell lymphomaTA370
Electrical stimulation of the lower oesophageal sphincter for treating gastro-oesophageal reflux diseaseHTG395
Repetitive transcranial magnetic stimulation for depressionHTG396
Joint distraction for ankle osteoarthritisHTG393
Radiofrequency ablation for symptomatic interdigital (Morton's) neuromaHTG394
Insertion of a subretinal prosthesis system for retinitis pigmentosaHTG392
Oral health promotion: general dental practiceNG30
Transition between inpatient hospital settings and community or care home settings for adults with social care needsNG27
Children's attachment: attachment in children and young people who are adopted from care, in care or at high risk of going into careNG26
Ledipasvir–sofosbuvir for treating chronic hepatitis CTA363
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis CTA365
Vortioxetine for treating major depressive episodesTA367
Implantation of a corneal graft–keratoprosthesis for severe corneal opacity in wet blinking eyesHTG389
Living-donor liver transplantationHTG390
Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retentionHTG391
Blood transfusionNG24
VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesionsHTG388
Older people with social care needs and multiple long-term conditionsNG22
Developing and updating local formulariesMPG1
Tolvaptan for treating autosomal dominant polycystic kidney diseaseTA358
Idelalisib for treating chronic lymphocytic leukaemiaTA359
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal)TA362
Implanting a baroreceptor stimulation device for resistant hypertensionHTG387

Results per page

  1. 10
  2. 25
  3. 50
  4. All